Lv3
212 积分 2022-04-18 加入
Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy
27天前
已完结
Assessment of Neutralizing Antibody Activity in Clinical Studies: Use of Surrogate Measurements Instead of Stand-alone Assays
5个月前
已完结
Whole Blood Or Plasma: What is the Ideal Matrix for pharmacokinetic-driven Drug Candidate selection?
6个月前
已完结
Regulated bioanalysis of antibody-drug conjugates using LC-MS
7个月前
已完结
Bioanalysis for PK for antibody drug conjugates using ligand binding assay–challenges and bioanalytical strategies
7个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
8个月前
已完结
Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium
8个月前
已完结
Cross-validation of pharmacokinetic assays post-ICH M10 is not a pass/fail criterion
8个月前
已完结
Development and Validation of a Cell-Based Binding Neutralizing Antibody Assay for an Antibody–Drug Conjugate
9个月前
已完结
皖公网安备34019202002308
